Figure 3.
mm-SW evolution during induction and consolidation therapy as per AIEOP-BFM ALL 2009 protocol. Of 73 CD371pos BCP-ALL samples evaluable for MFC MRD from the screening cohort (AIEOP), the mm-SW was observed (detection limit, 1 × 10−4) since the first reevaluation time point on day 8 or later on day 15 and day 33. It was never detected on day 78 in the screening cohort. N, number of samples; SW+, presence of lineage SW; SW−, absence of lineage-SW population; SW NA, MCF-MRD not available.

mm-SW evolution during induction and consolidation therapy as per AIEOP-BFM ALL 2009 protocol. Of 73 CD371pos BCP-ALL samples evaluable for MFC MRD from the screening cohort (AIEOP), the mm-SW was observed (detection limit, 1 × 10−4) since the first reevaluation time point on day 8 or later on day 15 and day 33. It was never detected on day 78 in the screening cohort. N, number of samples; SW+, presence of lineage SW; SW−, absence of lineage-SW population; SW NA, MCF-MRD not available.

Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal